133 related articles for article (PubMed ID: 38064771)
1. Non-targeted metabolomics study for discovery of hepatocellular carcinoma serum diagnostic biomarker.
Wang S; He T; Wang H
J Pharm Biomed Anal; 2024 Feb; 239():115869. PubMed ID: 38064771
[TBL] [Abstract][Full Text] [Related]
2. Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS.
Fitian AI; Nelson DR; Liu C; Xu Y; Ararat M; Cabrera R
Liver Int; 2014 Oct; 34(9):1428-44. PubMed ID: 24661807
[TBL] [Abstract][Full Text] [Related]
3. LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort.
Xiao JF; Varghese RS; Zhou B; Nezami Ranjbar MR; Zhao Y; Tsai TH; Di Poto C; Wang J; Goerlitz D; Luo Y; Cheema AK; Sarhan N; Soliman H; Tadesse MG; Ziada DH; Ressom HW
J Proteome Res; 2012 Dec; 11(12):5914-23. PubMed ID: 23078175
[TBL] [Abstract][Full Text] [Related]
4. Development of urinary pseudotargeted LC-MS-based metabolomics method and its application in hepatocellular carcinoma biomarker discovery.
Shao Y; Zhu B; Zheng R; Zhao X; Yin P; Lu X; Jiao B; Xu G; Yao Z
J Proteome Res; 2015 Feb; 14(2):906-16. PubMed ID: 25483141
[TBL] [Abstract][Full Text] [Related]
5. Metabolomic Characterization of Hepatocellular Carcinoma in Patients with Liver Cirrhosis for Biomarker Discovery.
Di Poto C; Ferrarini A; Zhao Y; Varghese RS; Tu C; Zuo Y; Wang M; Nezami Ranjbar MR; Luo Y; Zhang C; Desai CS; Shetty K; Tadesse MG; Ressom HW
Cancer Epidemiol Biomarkers Prev; 2017 May; 26(5):675-683. PubMed ID: 27913395
[No Abstract] [Full Text] [Related]
6. Tissue and serum metabolomic phenotyping for diagnosis and prognosis of hepatocellular carcinoma.
Han J; Han ML; Xing H; Li ZL; Yuan DY; Wu H; Zhang H; Wang MD; Li C; Liang L; Song YY; Xu AJ; Wu MC; Shen F; Xie Y; Yang T
Int J Cancer; 2020 Mar; 146(6):1741-1753. PubMed ID: 31361910
[TBL] [Abstract][Full Text] [Related]
7. Pseudotargeted metabolomics method and its application in serum biomarker discovery for hepatocellular carcinoma based on ultra high-performance liquid chromatography/triple quadrupole mass spectrometry.
Chen S; Kong H; Lu X; Li Y; Yin P; Zeng Z; Xu G
Anal Chem; 2013 Sep; 85(17):8326-33. PubMed ID: 23889541
[TBL] [Abstract][Full Text] [Related]
8. NMR and LC/MS-based global metabolomics to identify serum biomarkers differentiating hepatocellular carcinoma from liver cirrhosis.
Liu Y; Hong Z; Tan G; Dong X; Yang G; Zhao L; Chen X; Zhu Z; Lou Z; Qian B; Zhang G; Chai Y
Int J Cancer; 2014 Aug; 135(3):658-68. PubMed ID: 24382646
[TBL] [Abstract][Full Text] [Related]
9. Targeted metabolic profiling of hepatocellular carcinoma and hepatitis C using LC-MS/MS.
Baniasadi H; Gowda GA; Gu H; Zeng A; Zhuang S; Skill N; Maluccio M; Raftery D
Electrophoresis; 2013 Oct; 34(19):2910-7. PubMed ID: 23856972
[TBL] [Abstract][Full Text] [Related]
10. Metabolomic Analysis of Liver Tissues for Characterization of Hepatocellular Carcinoma.
Ferrarini A; Di Poto C; He S; Tu C; Varghese RS; Kara Balla A; Jayatilake M; Li Z; Ghaffari K; Fan Z; Sherif ZA; Kumar D; Kroemer A; Tadesse MG; Ressom HW
J Proteome Res; 2019 Aug; 18(8):3067-3076. PubMed ID: 31188000
[TBL] [Abstract][Full Text] [Related]
11. Metabonomic profiles discriminate hepatocellular carcinoma from liver cirrhosis by ultraperformance liquid chromatography-mass spectrometry.
Wang B; Chen D; Chen Y; Hu Z; Cao M; Xie Q; Chen Y; Xu J; Zheng S; Li L
J Proteome Res; 2012 Feb; 11(2):1217-27. PubMed ID: 22200553
[TBL] [Abstract][Full Text] [Related]
12. Integrated microbiome and metabolome analysis reveals the interaction between intestinal flora and serum metabolites as potential biomarkers in hepatocellular carcinoma patients.
Li X; Yi Y; Wu T; Chen N; Gu X; Xiang L; Jiang Z; Li J; Jin H
Front Cell Infect Microbiol; 2023; 13():1170748. PubMed ID: 37260707
[TBL] [Abstract][Full Text] [Related]
13. Utilization of metabolomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis.
Ressom HW; Xiao JF; Tuli L; Varghese RS; Zhou B; Tsai TH; Ranjbar MR; Zhao Y; Wang J; Di Poto C; Cheema AK; Tadesse MG; Goldman R; Shetty K
Anal Chim Acta; 2012 Sep; 743():90-100. PubMed ID: 22882828
[TBL] [Abstract][Full Text] [Related]
14. Biomarker Discovery for Hepatocellular Carcinoma in Patients with Liver Cirrhosis Using Untargeted Metabolomics and Lipidomics Studies.
Rashid MM; Varghese RS; Ding Y; Ressom HW
Metabolites; 2023 Oct; 13(10):. PubMed ID: 37887372
[TBL] [Abstract][Full Text] [Related]
15. LC-MS/MS and SWATH based serum metabolomics enables biomarker discovery in pancreatic cancer.
Xiong Y; Shi C; Zhong F; Liu X; Yang P
Clin Chim Acta; 2020 Jul; 506():214-221. PubMed ID: 32243985
[TBL] [Abstract][Full Text] [Related]
16. Serum Metabolomics to Identify the Liver Disease-Specific Biomarkers for the Progression of Hepatitis to Hepatocellular Carcinoma.
Gao R; Cheng J; Fan C; Shi X; Cao Y; Sun B; Ding H; Hu C; Dong F; Yan X
Sci Rep; 2015 Dec; 5():18175. PubMed ID: 26658617
[TBL] [Abstract][Full Text] [Related]
17. A novel analysis method for biomarker identification based on horizontal relationship: identifying potential biomarkers from large-scale hepatocellular carcinoma metabolomics data.
Su B; Luo P; Yang Z; Yu P; Li Z; Yin P; Zhou L; Fan J; Huang X; Lin X; Qiao Y; Xu G
Anal Bioanal Chem; 2019 Sep; 411(24):6377-6386. PubMed ID: 31384984
[TBL] [Abstract][Full Text] [Related]
18. [High-performance liquid chromatography-mass spectrometry-based serum metabolic profiling in patients with HBV-related hepatocellular carcinoma].
Zhang L; Fan Z; Kang H; Wang Y; Liu S; Shan Z
Nan Fang Yi Ke Da Xue Xue Bao; 2019 Jan; 39(1):49-56. PubMed ID: 30692066
[TBL] [Abstract][Full Text] [Related]
19. Chromatographic determination of some biomarkers of liver cirrhosis and hepatocellular carcinoma in Egyptian patients.
Osman D; Ali O; Obada M; El-Mezayen H; El-Said H
Biomed Chromatogr; 2017 Jun; 31(6):. PubMed ID: 27862090
[TBL] [Abstract][Full Text] [Related]
20. UHPLC-HRMS-based Multiomics to Explore the Potential Mechanisms and Biomarkers for Colorectal Cancer.
Wang X; Guan X; Tong Y; Liang Y; Huang Z; Wen M; Luo J; Chen H; Yang S; She Z; Wei Z; Zhou Y; Qi Y; Zhu P; Nong Y; Zhang Q
BMC Cancer; 2024 May; 24(1):644. PubMed ID: 38802800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
